Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells

被引：363

作者：

Grasberger, BL ^{[1
]}

Lu, TB ^{[1
]}

Schubert, C ^{[1
]}

Parks, DJ ^{[1
]}

Carver, TE ^{[1
]}

Koblish, HK ^{[1
]}

Cummings, MD ^{[1
]}

LaFrance, LV ^{[1
]}

Milkiewicz, KL ^{[1
]}

Calvo, RR ^{[1
]}

Maguire, D ^{[1
]}

Lattanze, J ^{[1
]}

Franks, CF ^{[1
]}

Zhao, SY ^{[1
]}

Ramachandren, K ^{[1
]}

Bylebyl, GR ^{[1
]}

Zhang, M ^{[1
]}

Manthey, CL ^{[1
]}

Petrella, EC ^{[1
]}

Pantoliano, MW ^{[1
]}

Deckman, IC ^{[1
]}

Spurlino, JC ^{[1
]}

Maroney, AC ^{[1
]}

Tomczuk, BE ^{[1
]}

Molloy, CJ ^{[1
]}

Bone, RF ^{[1
]}

机构：

[1] Johnson & Johnson Pharmaceut Res & Dev LLC, Exton, PA 19341 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2005年 / 48卷 / 04期

关键词：

D O I：

10.1021/jm049137g

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

HDM2 binds to an a-helical transactivation domain of p53, inhibiting its tumor suppressive functions. A miniaturized thermal denaturation assay was used to screen chemical libraries, resulting in the discovery of a novel series of benzodiazepinedione antagonists of the HDM2-p53 interaction. The X-ray crystal structure of improved antagonists bound to HDM2 reveals their a-helix mimetic properties. These optimized molecules increase the transcription of p53 target genes and decrease proliferation of tumor cells expressing wild-type p53.

引用

页码：909 / 912

页数：4

共 24 条

[1] Stochastic algorithms for maximizing molecular diversity [J].

Agrafiotis, DK .

JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 1997, 37 (05) :841-851

[2] Combinatorial informatics in the post-genomics era [J].

Agrafiotis, DK ;

Lobanov, VS ;

Salemme, FR .

NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (05) :337-346

[3] The proliferation of normal human fibroblasts is dependent upon negative regulation of p53 function by mdm2 [J].

Blaydes, JP ;

Wynford-Thomas, D .

ONCOGENE, 1998, 16 (25) :3317-3322

[4] Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo [J].

Bottger, A ;

Bottger, V ;

Sparks, A ;

Liu, WL ;

Howard, SF ;

Lane, DP .

CURRENT BIOLOGY, 1997, 7 (11) :860-869

[5] Molecular characterization of the hdm2-p53 interaction [J].

Bottger, A ;

Bottger, V ;

GarciaEcheverria, C ;

Chene, P ;

Hochkeppel, HK ;

Sampson, W ;

Ang, K ;

Howard, SF ;

Picksley, SM ;

Lane, DP .

JOURNAL OF MOLECULAR BIOLOGY, 1997, 269 (05) :744-756

[6]

Bottger V, 1996, ONCOGENE, V13, P2141

[7] A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines [J].

Chène, P ;

Fuchs, J ;

Bohn, J ;

García-Echeverría, C ;

Furet, P ;

Fabbro, D .

JOURNAL OF MOLECULAR BIOLOGY, 2000, 299 (01) :245-253

[8] A nonpeptidic sulfonamide inhibits the p53-mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells [J].

Galatin, PS ;

Abraham, DJ .

JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (17) :4163-4165

[9] Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain [J].

Kussie, PH ;

Gorina, S ;

Marechal, V ;

Elenbaas, B ;

Moreau, J ;

Levine, AJ ;

Pavletich, NP .

SCIENCE, 1996, 274 (5289) :948-953

[10] Development of a potent Bcl-xL antagonist based on α-helix mimicry [J].

Kutzki, O ;

Park, HS ;

Ernst, JT ;

Orner, BP ;

Yin, H ;

Hamilton, AD .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2002, 124 (40) :11838-11839

← 1 2 3 →